




Contact: Eric Buckland
Location: RTP, NC
Email: ebuckland@bioptigen.com
Tel: 919. 314.5502
Website: <http://www.bioptigen.com>



Company Profile

Industry Sector: Medical Devices, Imaging

Company Overview: Bioptigen's pioneering in vivo optical imaging technology allows researchers and clinicians to see pathologies at their earliest stages. The sophisticated SDOCT hardware and software system enables real-time non invasive imaging of internal tissue microstructure at an unmatched level of precision and depth. Our system extends the application space to cover a wide range of human and animal subjects. These advances make it possible for [researchers](#) to open up new avenues of biological exploration and development, and [clinicians](#) to foster advances in disease detection and management.

Target Market(s): Academic and industrial research ophthalmology, clinical ophthalmology.

FDA 510(k) clearance received 2006

Key Value Drivers

Technology: Bioptigen Spectral Domain Optical Coherence Tomography is a non-invasive imaging technique using spectral interferometry to obtain high resolution depth-resolved images of biological tissue in real-time.

Competitive Advantage: Bioptigen offers the highest resolution, greatest imaging depth, and most versatile system for real-time imaging.

Plan & Strategy: Bioptigen is leveraging its position in the research market to develop and deliver advanced imaging tools to improve clinical healthcare.



Management

Leadership:

Eric Buckland, PhD, Co-Founder, President and CEO
 Joseph Izatt, PhD, Co-Founder, Chairman and CTO
 Tom Sekel, VP Financial Operations
 Robert Hart, Director of Product Development
 Bennett Groshong, Director of Software Development
 Eric Schneider, Director of Manufacturing

Lead Adopters:

Dr. Cynthia Toth, Professor of Ophthalmology Vitreoretinal Diseases and Surgery, Duke University
 Dr. Joel Schuman, Professor and Chairman of Ophthalmology, University of Pittsburgh

Product Pipeline

